Adicet is trying to turn prula-cel from a promising autoimmune CAR-T idea into a pivotal-trial story before its disclosed runway reaches the second half of 2027.
References
Sources used in this report
SEC submissionsSEC submissions JSON for CIK 00017205802026-05-13 · Issuer identity, ticker, exchange, filing inventory, annual report, quarterly report, current reports, and proxy confirmation.SEC XBRL companyfactsSEC companyfacts for CIK 00017205802026-05-13 · Standardized financial fact context for cross-checking filed financial data.Annual reportFY2025 Form 10-K2026-03-12 · Business description, pipeline, risks, segment reporting, no-product-revenue disclosure, accumulated deficit, financing history, collaboration disclosure, and manufacturing risk.Quarterly reportQ3 2025 Form 10-Q2025-11-05 · Latest quarterly report available in SEC submissions before the Q1 2026 earnings release; used for interim liquidity and pre-FY context.Earnings releaseQ1 2026 earnings release, Exhibit 99.12026-05-13 · Q1 2026 financial results, cash runway, prula-cel clinical update timing, FDA interaction timing, outpatient-dosing alignment, RA conditioning trial, and ADI-212 timing.Earnings releaseFY2025 earnings release, Exhibit 99.12026-03-12 · FY2025 expense trends, net loss, year-end cash, October 2025 offering proceeds, and runway disclosure.Corporate updateJanuary 2026 corporate update, Exhibit 99.12026-01-07 · All seven prula-cel cohorts enrolling, first AAV patient dosed, RA reduced-conditioning trial emphasis, and prior pipeline-timing context.Proxy statement2026 definitive proxy statement2026-04-29 · Annual meeting, share count, director nominees, executive officers, principal stockholders, RA Capital prefunded-warrant blocker, and related-person transaction policy.Peer annual reportAllogene Therapeutics FY2025 Form 10-K2026-03-12 · Competitive context for allogeneic CAR-T, autoimmune programs, lymphodepletion, manufacturing, and proof-of-concept gates.